Barclays Rates Bruker (BRKR) buy, $60 Price Target

Barclays maintains its buy rating for Bruker, setting a price target of $60, a 1.46% downside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 11:01 AM EDT · Updated Jun 26, 2026, 3:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays rated Bruker Corporation ($BRKR) "buy" with a $60 price target on June 24, 2026.

Since the rating, $BRKR is up 3.8% after 1 week, up 3.4% after 1 month and down 6.2% to date (from the $58.39 close on Jun 24, 2026).

BRKR Bruker Corporation

$54.80 +14.26% year to date

Daily close · Oct 16, 2026

Key Points

Barclays reiterated its buy rating for Bruker Corporation (NASDAQ: BRKR) with a $60 price target on June 24, 2026.
Barclays's $60 price target implies 1.46% downside from Bruker Corporation's ($BRKR) current $60.89 share price.
Bruker shares traded at $55.11 on Wednesday, with a market cap of approximately $8.61 billion and a forward P/E of 23.20.
ORBIS ALLAN GRAY LTD increased its Bruker holdings by 3,033,346 shares, while Vanguard Portfolio Management LLC opened a new position with 4,855,915 shares.

Get $BRKR trade alerts by text

We text you when insiders, Congress or big funds trade $BRKR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bruker Corporation alert may contain errors. Disclosures

Barclays reiterated its buy rating for Bruker Corporation, trading under the ticker BRKR on the NasdaqGS, on June 24, 2026. Analyst Luke Sergott set a price target of $60. On the same day, Bruker's shares traded at $55.11.

Analyst rating track record

Barclays vs. the S&P 500

YTD return +22.25% hypothetical

All-time return +39.40% S&P 500 +39.12%

vs. S&P 500 +0.28% ahead of the index

Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Bruker Corporation

ORBIS ALLAN GRAY LTD increased its holdings in Bruker by 3,033,346 shares, bringing its total to 17,940,076 shares valued at approximately $648 million, marking a 20.3% increase. FMR LLC also grew its stake by 872,177 shares to 16,101,803 shares, valued at about $582 million, a 5.7% increase. BlackRock, Inc. added 208,821 shares, ending with 11,180,806 shares worth roughly $404 million, a 1.9% increase. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 4,855,915 shares valued at around $175 million.

Bruker Corporation Stock Down 0.7%

Shares of Bruker Corporation (NASDAQ: BRKR) traded near $55.11 on Wednesday. The company has a market capitalization of approximately $8.61 billion and a forward P/E ratio of 23.20. Bruker's stock has seen a 52-week low of $28.53 and a high of $64.54, with a 50-day moving average of $45.95 and a 200-day moving average of $41.85. The company maintains a current ratio of 1.55 and a quick ratio of 0.65, with a debt-to-equity ratio of 68.12.

12-month forecast

$BRKR price target

Bruker Corporation daily closes and this analyst's $60 target. Not advice.

Recent Earnings

Bruker Corporation reported revenue of about $3.46 billion, reflecting a revenue growth of 2.7%. However, the company has a negative net margin of -0.34% and a return on equity of -0.43%. The next earnings report is scheduled for August 4, 2026.

Dividend

Bruker Corporation pays an annual dividend rate of $0.20, yielding 0.35%. The dividend payout ratio stands at 38.46%.

Insider Buying and Selling at Bruker Corporation

On June 15, 2026, Mark Munch, Executive Vice President and President of Bruker Nano Inc., sold 2,000 shares at an average price of $54.76. On the same day, he also purchased 2,000 shares at $22.19. Additionally, Thierry Bernard acquired 2,886 shares on May 15, 2026.

Analysts Set New Price Targets

On June 24, 2026, Barclays maintained its buy rating for Bruker Corporation with a price target of $60. Earlier, on June 8, 2026, JP Morgan also maintained a buy rating with a target of $65. The consensus among analysts is a buy rating, with a mean price target of $53.25 based on 12 opinions.

About Bruker Corporation

Bruker Corporation, headquartered in Billerica, Massachusetts, develops and manufactures scientific instruments and analytical solutions. The company operates through segments including BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers a range of products such as magnetic resonance spectroscopy, preclinical imaging, and mass spectrometry solutions. Led by CEO Dr. Frank H. Laukien, Bruker employs approximately 11,085 people.

Bottom Line

Barclays' reiteration of its buy rating for Bruker Corporation reflects confidence in the company's prospects, despite its recent financial challenges. Investors often track these ratings to gauge market sentiment. Remember, these analyst updates are based on data as of the report date and may not reflect current conditions.